Barry Richard

Average Profitability
9.42%
Insider Buys Quantity
12
Insider Buys Sum
$10.12M
Insider Sells Quantity
3
Insider Sells Sum
$28.54M

Insider Activity of Barry Richard

The largest purchase of all time was on 2023-11-03 and amounted to 50000 shares of Sarepta Therapeutics, Inc. for $3.94M.

The largest sale of all time was on 2018-06-27 and amounted to 150000 shares of Sarepta Therapeutics, Inc. for $19.55M.

Biography of Barry Richard

No biography is available at this moment.

2023-11-03PurchaseSarepta Therapeutics, Inc.
SRPT
director
50,000
0.0542%
$78.81$3.94M+59.43%
2023-08-22PurchaseCassava Sciences, Inc.
SAVA
director
16,571
0.0382%
$16.65$275,907+24.23%
2023-08-21PurchaseCassava Sciences, Inc.
SAVA
director
1,906
0.0046%
$16.80$32,021+27.38%
2023-03-07PurchaseCassava Sciences, Inc.
SAVA
director
77,276
0.1893%
$25.76$1.99M-9.92%
2023-03-06PurchaseCassava Sciences, Inc.
SAVA
director
11,565
0.0275%
$26.13$302,193-13.62%
2022-08-23PurchaseCassava Sciences, Inc.
SAVA
36,159
0.0849%
$23.79$860,223+3.97%
2020-08-07SaleSarepta Therapeutics, Inc.
SRPT
director
30,000
0.0381%
$158.50$4.75M-43.45%
2020-05-15SaleSarepta Therapeutics, Inc.
SRPT
director
30,000
0.0385%
$141.26$4.24M-0.2%
2019-09-13PurchaseSarepta Therapeutics, Inc.
SRPT
director
3,309
0.0045%
$87.49$289,504+41.5%
2019-09-12PurchaseSarepta Therapeutics, Inc.
SRPT
director
1,691
0.0023%
$87.49$147,950+38.3%
2019-08-20PurchaseSarepta Therapeutics, Inc.
SRPT
director
5,000
0.0066%
$99.32$496,593+15.54%
2019-08-14PurchaseSarepta Therapeutics, Inc.
SRPT
director
3,700
0.0049%
$122.50$453,250-4.62%
2019-08-12PurchaseSarepta Therapeutics, Inc.
SRPT
director
1,300
0.0017%
$122.50$159,250-5.04%
2018-06-27SaleSarepta Therapeutics, Inc.
SRPT
director
150,000
0.231%
$130.34$19.55M-2.85%
2016-03-14PurchaseSarepta Therapeutics, Inc.
SRPT
director
75,000
0.1544%
$15.66$1.17M+66.5%
Company
About Prismo.proNewsPrivacy PolicyTerms of ServiceContact Us
Investing Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny Stocks
Stock Tools
Insiders ScreenerStocks ScreenerTop StocksList of All Stocks
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.